Table 1

Patient characteristics

Conventional hydrationShort hydration
n=356% or rangen=111% or range
Age (years)
 Median (range)6127–696333–69
Sex
 Female10830.33632.4
 Male24869.77567.6
Performance status
 018852.85045.1
 115844.35953.1
 282.321.8
 320.600
Treatment setting
 Advanced disease15242.75852.3
 Chemoradiotherapy10429.22320.7
 Adjuvant therapy6618.52118.9
 Postsurgical recurrence349.698.1
Treatment regimen
 Cisplatin+Vinorelbine13738.43834.2
 Cisplatin+Pemetrexed9526.75347.8
 Cisplatin+Irinotecan5816.343.6
 Cisplatin+Etoposide308.443.6
 Cisplatin+Docetaxel267.376.3
 Cisplatin+Gemcitabine82.354.5
 Cisplatin+Amrubicin20.600
Histology
 Adenocarcinoma20457.58374.8
 Squamous cell carcinoma4211.81614.4
 NSCLC143.943.6
 Small cell carcinoma7320.654.5
 LCNEC143.932.7
 MPM82.300
Comorbidities
 Hypertension9827.52522.5
 Diabetes mellitus205.621.8
 Cardiac disease174.800
 Pulmonary disease4312.11311.7
Magnesium supplementation29582.911099.0
  • LCNEC, large-cell neuroendocrine carcinoma; MPM, malignant pleural mesothelioma NSCLC, non-small cell lung cancer.